This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Hepatic disease				
Hepatic disease	Complement receptor 2 (CR2); CD59; complement C5b-9 membrane attack complex (MAC)	<p>Mouse studies suggest a CR2-CD59 fusion protein could help treat liver injury after transplantation surgery. In mouse models of hepatic ischemia/reperfusion injury or partial or massive hepatectomy, a mouse Cr2-Cd59 fusion protein migrated to sites of complement activation in the liver and inhibited MAC without also blocking other components of the complement system. In these models, the mouse Cr2-Cd59 fusion protein increased liver regeneration and decreased liver damage compared with vehicle. Next steps could include developing and testing a human version of the CR2-CD59 fusion protein.</p> <p>SciBX 7(35); doi:10.1038/scibx.2014.1043 Published online Sept. 11, 2014</p>	Patent and licensing status unavailable	<p>Marshall, K.M. <i>et al. J. Exp. Med.</i>; published online Aug. 11, 2014; doi:10.1084/jem.20131902 Contact: Stephen Tomlinson, Medical University of South Carolina, Charleston, S.C. e-mail: tomlinss@musc.edu</p>